Eligible patients can receive up to 70% subsidies for hereditary cancer genetic testing.
Singapore is expanding access to preventive cancer care by subsidizing genetic testing for people at risk of Hereditary Breast and Ovarian Cancer, or HBOC. The initiative will begin on December 1, 2026, alongside stronger financial support for follow-up treatment and preventive interventions.
Testing Available at Three Healthcare Centers
Subsidized HBOC genetic testing will be available at specialist outpatient clinics at the National Cancer Centre Singapore, National University Cancer Institute Singapore, and Tan Tock Seng Hospital. Eligible groups include breast or ovarian cancer patients with HBOC risk factors, first-degree relatives of people carrying HBOC-associated genetic variants, and individuals with a strong family history of HBOC whose cancer-affected relatives are unavailable for testing. Eligibility applies regardless of gender.
Eligible Patients Can Receive Up to 70% Subsidies
Eligible Singapore citizens and permanent residents can receive means-tested subsidies of up to 70% for HBOC genetic testing, with additional support for Pioneer and Merdeka Generation seniors. An initial test costs approximately S$1,000 before subsidies, and patients can use MediSave to offset the remaining amount, potentially eliminating out-of-pocket expenses if they have sufficient balances. Eligible relatives may also receive subsidized cascade testing, with MediSave available to help cover the cost.
Around 2,000 People Could Benefit Annually
MOH estimates that approximately 2,000 people annually, including relatives of individuals who test positive, could benefit from subsidized HBOC genetic testing. Around one in 150 Singaporeans carries an HBOC-associated genetic variant, and women with these variants face a fivefold to tenfold higher lifetime risk of developing breast or ovarian cancer compared with the general female population. The variants can be inherited by both males and females.
Support Extends Beyond Genetic Testing
Individuals who test positive for HBOC-associated genetic variants may be advised to undergo intensified cancer surveillance, preventive surgery, or medication to reduce their risk. MediShield Life and MediSave already provide coverage for risk-reducing mastectomy, while similar coverage for preventive removal of the fallopian tubes and ovaries is expected by the end of 2026. Annual breast MRI scans and mammograms can also be financed through existing MediSave outpatient scan limits, subject to eligibility and withdrawal limits.
Singapore Strengthens Preventive Cancer Care
The initiative reflects Singapore’s broader efforts to strengthen preventive and personalized healthcare by identifying people with inherited cancer risks and making early intervention more accessible. MOH said that improving access to genetic testing and follow-up care could help reduce the burden of hereditary cancers on individuals, families, and the healthcare system. The ministry also said it would continue reviewing measures that support early detection and timely intervention.
Singapore’s new financing framework makes hereditary cancer testing and recommended preventive care more accessible to eligible patients while extending support to family members who may carry the same genetic variants. For Singaporeans, the program expands opportunities for earlier risk identification and intervention. Indonesians living in Singapore may also benefit if they hold Permanent Resident status and meet the required clinical criteria, making the policy relevant to families with cross-border ties and hereditary cancer concerns.
Sources: Straits Times (2026) , Open Gov Asia (2026)
Keywords: Singapore Genetic Testing, Hereditary Cancer Testing, HBOC Screening, Breast Cancer Risk, Ovarian Cancer Risk, Healthcare Subsidies
